Literature DB >> 12204864

Smoking and lung function of Lung Health Study participants after 11 years.

Nicholas R Anthonisen1, John E Connett, Robert P Murray.   

Abstract

Eleven years after Lung Health Study (LHS) entry, we performed spirometry in 77.4% of surviving participants who enrolled in a long-term follow-up study. Those not enrolling tended to be younger male heavy smokers who continued to smoke during the LHS. Their initial LHS lung function, after adjustment for these factors, did not differ from that of enrollees. Smoking habits by original LHS treatment groups (smoking intervention vs. usual care) tended to converge, but 93% of participants who were abstinent throughout the LHS were still abstinent at 11 years. Differences in lung function between treatment groups persisted; smoking intervention participants had less decline in FEV(1) than usual care participants. Men who quit at the beginning of the LHS had an FEV(1) rate of decline of 30.2 ml/year, whereas women who quit declined at 21.5 ml/year. Men continuing to smoke throughout the 11 years declined by 66.1 ml/year, and women continuing to smoke declined by 54.2 ml/year. When decline in FEV(1) was expressed as a percentage of predicted normal value, no significant sex-based difference was apparent among continuing smokers. At 11 years, 38% of continuing smokers had an FEV(1) less than 60% of the predicted normal value compared with 10% of sustained quitters.

Entities:  

Mesh:

Year:  2002        PMID: 12204864     DOI: 10.1164/rccm.2112096

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  175 in total

1.  Chronic obstructive pulmonary disease.

Authors:  David Price; Martin Duerden
Journal:  BMJ       Date:  2003-05-17

Review 2.  The problem of tobacco smoking.

Authors:  Richard Edwards
Journal:  BMJ       Date:  2004-01-24

3.  Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease.

Authors:  M Zhang; Q Li; X-Y Zhang; X Ding; D Zhu; X Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-20       Impact factor: 3.267

Review 4.  Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; P Bartsch; C-G Löfdahl; W Vincken; R Dekhuijzen; J Vestbo; R Pauwels; R Naeije; T Troosters
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

5.  "Susceptible" smokers?

Authors:  N R Anthonisen
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

6.  Pharmacokinetics of a novel agent, R667, in patients with emphysema.

Authors:  Yu-Yuan Chiu; Michael D Roth; Stanley Kolis; David Rogovitz; Brian Davies
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

7.  Exposure to PM10 as a risk factor for the development of nasal obstruction and chronic obstructive pulmonary disease.

Authors:  Lazaros Sichletidis; Dionisios Spyratos; Anastasios Tsiotsios; Anna-Bettina Haidich; Ioannis Ganidis; Dimitrios Michailidis; Georgios Triantafyllou; George Kottakis; Dimitrios Melas
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

8.  Developing COPD: a 25 year follow up study of the general population.

Authors:  A Løkke; P Lange; H Scharling; P Fabricius; J Vestbo
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

Review 9.  Multidisciplinary care of the patient with chronic obstructive pulmonary disease.

Authors:  Anne Marie Kuzma; Yvonne Meli; Catherine Meldrum; Patricia Jellen; Marianne Butler-Lebair; Debra Koczen-Doyle; Peter Rising; Kim Stavrolakes; Frances Brogan
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Cigarette smoking and pulmonary function in adult survivors of childhood cancer exposed to pulmonary-toxic therapy: results from the St. Jude lifetime cohort study.

Authors:  S Cristina Oancea; James G Gurney; Kirsten K Ness; Rohit P Ojha; Vida L Tyc; James L Klosky; DeoKumar Srivastava; Dennis C Stokes; Leslie L Robison; Melissa M Hudson; Daniel M Green
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.